China NMPA Drug Inspection - Qinhuangdao Dexin Pharmaceutical Co., Ltd. - Angelica sinensis

The Hebei Provincial Drug Administration announced drug quality issues identified during supervision and sampling inspections conducted from April to June 2019. Qinhuangdao Dexin Pharmaceutical Co., Ltd. was found to have produced two batches of non-compliant traditional Chinese medicines. Specifically, Lily bulbs (batch number 160801) and Angelica sinensis (batch number 170901) failed to meet quality standards in the 'Appearance' category. In response, regulatory departments initiated control measures, including sealing and seizing the substandard products. The company faces investigations into its production and sales activities under Articles 73, 74, and 75 of the 'Drug Administration Law of the People's Republic of China'. Authorities are required to announce risk control measures within one week and publicly disclose the resolution of these issues within three months. Any suspected counterfeit drugs are to be thoroughly investigated, with potential criminal matters referred to public security departments. All pertinent information must be reported to the Provincial Drug Administration's Inspection Division.